Shenzhen haipuri Pharmaceutical Co., Ltd. (002399)

Shenzhen haipuri Pharmaceutical Co., Ltd. (002399)

Founded in Shenzhen, China in 1998, heppery was the founder of "bringing good news to patients as its own responsibility and becoming an international leading pharmaceutical enterprise". With continuous and unremitting efforts, heppery has set up an integrated safety supply chain in a full swing, becoming the largest heparin sodium API enterprise and the third largest enoxaparin preparation Enterprise in the world. In the EU, preparations of "inhixa" and "neoparin" brands are being sold on a large scale. In China, the brand of "Ploquin" has become the second largest market brand after the original research brand. In addition to the above countries and regions, enoxaparin preparation has been approved for marketing in dozens of other countries and regions. The heparin industry chain business is creating a stable business for the company Increased cash flow.

While building the foundation of the company's development - deep cultivation of heparin industry chain, the founder of the company, as a sugar biochemistry expert, led the global R & D team to consistently study the role of heparin and its derivatives in the life process at the molecular biology level, especially in the field of immune regulation mechanism, and constructed the scientific logic of the layout of innovative drug pipelines - develop, explore and invest in the first in class in the cardiovascular and tumor diseases caused by immune imbalance to meet the major unmet clinical needs of high mortality. The company has the global asset rights and interests of several innovative new drugs and the commercial rights and interests of Greater China in several mid and later clinical varieties. With the gradual completion of clinical trials in the global scope of innovative drug varieties, not only our global rights and interests can be realized, but also the realization of commercial rights and interests in Greater China is also in the near future.

In order to expand the screening vision of innovative varieties and to screen new drugs more accurately, and to accelerate the development of existing pipeline varieties, the company wholly acquired cytovance, a biological macromolecular cdmo company with a global leading and unique technology system. Our bio macromolecular cdmo platform not only has strong microbial and mammalian cell business, but also focuses on the booming gene therapy market opportunities. With its high quality and unique technical services, our bio macromolecular cdmo platform has won the trust of the heavyweight customers worldwide, and is becoming another high-speed cash flow business of the company.

The integrated management system and best practice of global R & D, rapid transformation, production and operation and marketing of drugs, especially the innovative R & D pipeline, and the high growth cdmo business that has been empowered for innovation, have become the development advantages of heppery in the future.

Today, heppery will continue to carry out the lofty mission of bringing the gospel to the global patients.

China Safety Shoes Manufacturer >>  Safty Shoes OEM